ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Mark Schneyer sold 5,849 shares of the business’s stock in a transaction dated Wednesday, August 5th. ACADIA Pharmaceuticals Stock PerformanceShares of ACAD stock opened at $29.21 on Friday. Get ACADIA Pharmaceuticals alerts:ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. Zacks ACADIA earnings estimate outlookZacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. ACADIA Pharmaceuticals Company Profile(Get Free Report)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders.